9 Meters Biopharma (NASDAQ:NMTR) released its quarterly earnings data on Saturday. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.06), Fidelity Earnings reports.
9 Meters Biopharma stock opened at $0.83 on Monday. The business’s fifty day moving average is $0.76. 9 Meters Biopharma has a one year low of $0.44 and a one year high of $1.11.
Several research firms recently weighed in on NMTR. William Blair reissued a “buy” rating on shares of 9 Meters Biopharma in a report on Thursday, September 24th. Zacks Investment Research cut 9 Meters Biopharma from a “buy” rating to a “hold” rating in a report on Wednesday, October 14th. Brookline Capital Management began coverage on 9 Meters Biopharma in a report on Tuesday, August 18th. They set a “buy” rating and a $5.00 price target for the company. HC Wainwright reissued a “buy” rating on shares of 9 Meters Biopharma in a report on Monday, September 21st. Finally, Maxim Group began coverage on 9 Meters Biopharma in a report on Friday, October 30th. They set a “buy” rating for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. 9 Meters Biopharma has a consensus rating of “Buy” and a consensus target price of $5.00.
9 Meters Biopharma Company Profile
9 Meters Biopharma, Inc, a gastrointestinal platform company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 analogue for SBS; Larazotide, a Phase 3-stage therapeutic in development for celiac disease; and NM-003, a long-acting GLP-2 analogue, which is under orphan indication selection.
Further Reading: Pattern Day Trader – What is the PDT Rule?
Receive News & Ratings for 9 Meters Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 9 Meters Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.